Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran,...

Sibylla Biotech Enters a Strategic Drug Discovery Collaboration with Ono Pharmaceutical in Central Nervous System Disorders Milan, Italy, March 14, 2024 – Sibylla Biotech announced today a drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (TSE: 4528) that...

Sibylla Biotech Raises €23 Million Series A to Advance Protein Degradation by Folding Interference Pipeline and Expand Technology Platform Verona, Italy, October 4, 2022 – Sibylla Biotech today announced the successful close of its €23 million Series A financing round...

Sibylla Biotech selected by Nature among the eight best start-ups in the world in the life-science sector Sibylla Biotech, a spin-off of INFN, the University of Trento, and the University of Perugia, has been selected, the only Italian company, as a finalist of the...

Sibylla Biotech will use its Drug Discovery platform to modulate the activity of targets supplied by Takeda. The Italian startup company will partner its innovative PPI-FIT Drug Discovery platform with Takeda to generate novel compounds designed to modulate the...

Recent computational advancements in the simulation of biochemical processes allow investigating the mechanisms involved in protein regulation with realistic physics-based models, at an atomistic level of resolution.

A new structural target for drug development against COVID-19 has been unveiled today by Sibylla Biotech in collaboration with the Italian National Institute of Nuclear Physics (INFN), the University of Trento and University of Perugia.

A documentary on Sibylla Biotech broadcasted on TV 4.0 La fabbrica del futuro

Interview with one of the inventor of the PPI-FIT technology and co-founder of Sibylla Biotech 

Watch the interview in italian